Rong Sun

Rong Sun


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Pharmacological Research
Verified
Journal Article
Closed access
XLXiaojiaoyang Li
Xiaojiaoyang Li
RSRong Sun
Rong Sun
RLRunping Liu
Runping Liu

1 November 2018 in Phytomedicine
Verified
Journal Article
Closed access
XLXiaojiaoyang Li
Xiaojiaoyang Li
XLXiaoyu Li
Xiaoyu Li
NHNana Huang
Nana Huang
RLRunping Liu
Runping Liu
RSRong Sun
Rong Sun

11 March 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
XLXiaojiaoyang Li
Xiaojiaoyang Li
JGJunde Ge
Junde Ge
YLYajing Li
Yajing Li
YCYajie Cai
Yajie Cai
QZQi Zheng
Qi Zheng
RLRunping Liu
Runping Liu
Nonalcoholic fatty liver disease (NAFLD) has become one of the most prominent causes of chronic liver diseases and malignancies. However, few therapy has been approved. Radix Bupleuri (RB) is the most frequently used herbal medicine for the treatment of liver diseases. In the current study, we aim to systemically evaluate the therapeutic effects of saikosaponin A (SSa) and saikosaponin D (SSd), the major bioactive monomers in RB, against NAFLD and to investigate the underlying mechanisms. Our results demonstrated that both SSa and SSd improved diet-induced NAFLD. Integrative lipidomic and transcriptomic analysis revealed that SSa and SSd modulated glycerolipid metabolism by regulating related genes, like Lipe and Lipg. SSd profoundly suppressed the fatty acid biosynthesis by downregulating Fasn and Acaca expression and promoted fatty acid degradation by inducing Acox1 and Cpt1a expression. Bioinformatic analysis further predicted the implication of master transcription factors, including peroxisome proliferator-activated receptor alpha (PPARα), in the protective effects of SSa and SSd. These results were further confirmed in vitro in mouse primary hepatocytes. In summary, our study uncoded the complicated mechanisms underlying the promising anti-steatosis activities of saikosaponins (SSs), and provided critical evidence inspiring the discovery of innovative therapies based on SSa and SSd for the treatment of NAFLD and related complications.

1 January 2020
Verified
Book Chapter
Closed access
RLRunping Liu
Runping Liu
XLXiaojiaoyang Li
Xiaojiaoyang Li
NHNana Huang
Nana Huang
MFMengyue Fan
Mengyue Fan
RSRong Sun
Rong Sun

1 March 2020 in Phytomedicine
Verified
Journal Article
Closed access
XLXiaojiaoyang Li
Xiaojiaoyang Li
JGJunde Ge
Junde Ge
QZQi Zheng
Qi Zheng
JZJiaxiang Zhang
Jiaxiang Zhang
RSRong Sun
Rong Sun
RLRunping Liu
Runping Liu

1 September 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JBJinzhao Bai
Jinzhao Bai
YCYajie Cai
Yajie Cai
ZHZhiyan Huang
Zhiyan Huang
YGYiqing Gu
Yiqing Gu
NHNana Huang
Nana Huang
RLRunping Liu
Runping Liu
Constipation has become an epidemic enteric medical problem, accompanied with increasing long-term sequelae. Gut microbiota and serotonin (5-HT) have been believed as predominant player in the treatment of constipation. In clinical practices, Shouhui Tongbian Capsule (SHTB) was found to effectively improve constipation symptoms and promote gastrointestinal motility. However, the specific mechanism of SHTB is not clearly elucidated. Our current study aims to explore the therapeutic effects of SHTB against the development of constipation and the underlying mechanisms related to gut bacterial and 5-HT. We established loperamide hydrochloride (LH)-induced experimental constipation mouse model to evaluate the effect of SHTB. 16S RNA sequencing, fecal microbiota transplants (FMT), high performance liquid chromatograph, and molecular biological analysis were performed to investigate the potential mechanisms of SHTB. Our data demonstrated that SHTB significantly ameliorated LH-induced experimental constipation and accelerated enteric motility via promoting 5-HT biosynthesis in enterochromaffin cells and enteric neuron growth of the enteric nervous system (ENS) in both the small intestine and colon. Additionally, SHTB significantly modulated gut microbiota dysbiosis and potentially altered microbiota metabolites to enhance intestinal 5-HT production. Finally, FMT study confirmed that the effects of SHTB on 5-HT production and constipation are dependent on modulating intestinal microbiota dysbiosis. In conclusion, our current study deciphered therapeutic mechanism of SHTB in the treatment of experimental constipation from perspectives of gut microbiota-5-HT-intetinal motility axis and provides novel insights into the appropriate and safe application of SHTB in the clinic.